PTO/SB/08a (05-07)
Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Number		10743563	
Filing Date		2003-12-22	
First Named Inventor Jean-		n-Damien Charrier	
Art Unit		1625	
Examiner Name	Davis	, Zinna Northington	
Attorney Docket Number	er	VPI/02-131 US	
	Filing Date First Named Inventor Art Unit Examiner Name	Filing Date First Named Inventor Jean- Art Unit	

					U.S.I	PATENTS			Remove		
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue D)ate	Name of Patentee or Applicant of cited Document		Releva		Lines where ges or Relev	
	1	6525076	B1	2003-02	2-25	Millennium Pharmaceuticals, Inc.					
If you wis	h to a	⊥ dd additional U.S. Pater	⊥ nt citatio	n inform	ation pl	ease click the	Add button.		Add		
			U.S.P	ATENT	APPLI	CATION PUBI	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	ıtion	Name of Pate of cited Docu	entee or Applicant ment	Releva		Lines where ges or Relev	
	1	20040048797	A1	2004-03	3-11	Miller, et al.					
If you wis	h to a	⊥ dd additional U.S. Publi	⊥ shed Ap	l plication	n citatio	ı n information p	olease click the Add	l d button	Add		
				FOREIG	3N PAT	ENT DOCUM	ENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code ⁴	Publication Date	Name of Patented Applicant of cited Document	e or V	vhere Rel	or Relevant	T ₅
	1	00/067746	WO		A1	2000-11-16	Texas Biotechnolog Corporation	у			
	2	1203766	EP		A2	2002-05-08	Texas Biotechnolog Corporation	у			
	3	03/068242	WO		A1	2003-08-21	Vertex Pharmaceut Incorporated	icals			

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		10743563		
Filing Date		2003-12-22		
First Named Inventor	Jean-	Damien Charrier		
Art Unit		1625		
Examiner Name	Davis	, Zinna Northington		
Attorney Docket Number		VPI/02-131 US		

	4	01/94351	WO	A1	2001-12-13	Vertex Pharmaceuticals Incorporated		
If you wis	h to ac	dd additional Foreign Pa	atent Document	citation	information pl	ease click the Add buttor	Add	
			NON-PATEN	NT LITE	RATURE DO	CUMENTS	Remove	
Examiner Initials*	Cite No	(book madazine journal serial symnosium catalog etc.) date pages(s) yolume-issue number(s)						
	1	December 27, 2004 Office Action from U.S. Application No. 10/609,147						
	2	June 12, 2003 Office Action from U.S. Application No. 10/166,437						
	3	February 26, 2004 Office Action from U.S. Application No. 10/166,437						
	4	January 26, 2007 Office Action from U.S. Application No. 10/166,437						
If you wis	If you wish to add additional non-patent literature document citation information please click the Add button Add							
EXAMINER SIGNATURE								
Examiner Signature Date Considered								
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								
¹ See Kind Codes of USPTO Patent Documents at <u>www.USPTO.GOV</u> or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.								

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		10743563		
Filing Date		2003-12-22		
First Named Inventor	Jean-	Damien Charrier		
Art Unit		1625		
Examiner Name	Davis, Zinna Northington			
Attorney Docket Number		VPI/02-131 US		

Plea	Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):							
	That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).							
OR								
	That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filling of the information disclosure statement. See 37 CFR 1.97(e)(2).							
	See attached ce	rtification statement.						
X	Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.							
	None							
SIGNATURE A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.								
Sigr	nature	/Jennifer G. Che/	Date (YYYY-MM-DD)	2007-08-21				
Nan	ne/Print	Jennifer G. Che	Registration Number	58,035				
pub	lic which is to file	mation is required by 37 CFR 1.97 and 1.98 (and by the USPTO to process) an applications are setimated to take 1 hour to complete, inclu	on. Confidentiality is gover	ned by 35 U.S.C. 122 and 37 CFR				

application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria**,

CERTIFICATION STATEMENT

VA 22313-1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

- 1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
- A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
- 3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
- 4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
- 5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
- 6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
 - 9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.